Filing Overview
Registrant: Soaring Eagle Acquisition Corp., a special purpose acquisition company pursuing a business combination with Ginkgo Bioworks, Inc. The Form 8-K was furnished on September 8, 2021, under Item 7.01 (Regulation FD Disclosure), ahead of the September 14, 2021 special shareholder meeting.
Business Combination Update
- Soaring Eagle announced that it had achieved a quorum for the special meeting.
- Based on proxies submitted as of September 8, shareholders had voted overwhelmingly in favor of the proposed Business Combination and all other proposals scheduled for the meeting.
- The filing does not provide a specific vote count, approval percentage, redemption amount, or minimum trust-account balance.
- The registration statement was declared effective by the SEC on August 11, 2021, and the definitive proxy statement/prospectus had been mailed to shareholders as of August 10, 2021.
Financial and Liquidity Information
The filing does not report revenue, profit or loss, cash flow, margins, debt, liquidity, operating results, or other financial metrics. It also does not provide an updated valuation or third-party valuation of the proposed transaction.
Material Changes Versus Prior Period
The principal disclosed change is procedural: Soaring Eagle had obtained a quorum and reported strong preliminary proxy support for the proposed Business Combination. The filing does not present comparative financial information or quantify changes in the company’s financial condition.
Outlook, Risks, and Contingencies
- Completion remained subject to shareholder approval, satisfaction of transaction conditions, the minimum trust-account requirement after any redemptions, and applicable governmental or regulatory approvals.
- Risks included failure to close on time or at all, failure to obtain an extension of the business-combination deadline, termination rights under the merger agreement, litigation, Nasdaq listing risks, and volatility in Soaring Eagle’s securities.
- Additional risks related to disruption of Ginkgo’s business, employee retention, implementation of post-closing plans, competition and regulation in synthetic biology, and potential declines in demand for products using synthetic biology.
- The reported proxy support and anticipated meeting timing were forward-looking and could differ from the final voting results or transaction outcome.
- The Form 8-K and accompanying press release were furnished, not filed, for purposes of Section 18 of the Exchange Act, and were not incorporated by reference except as expressly stated.
Important Investor Verification Items
- Verify the final shareholder vote results from the September 14, 2021 special meeting.
- Verify the number of public-shareholder redemptions and the resulting trust-account balance.
- Confirm whether all closing conditions and required regulatory approvals were satisfied.
- Review the definitive proxy statement/prospectus and related risk factors for transaction terms, valuation, dilution, and capitalization details.
- Confirm whether and when the Business Combination closed and whether the combined company maintained its Nasdaq listing.